Mckinley Capital Management LLC Delaware Invests $10.77 Million in Neurocrine Biosciences, Inc. (NBIX)

Mckinley Capital Management LLC Delaware acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 138,824 shares of the company’s stock, valued at approximately $10,771,000. Mckinley Capital Management LLC Delaware owned approximately 0.16% of Neurocrine Biosciences as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of NBIX. Janus Henderson Group PLC boosted its position in Neurocrine Biosciences by 2.6% during the third quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock valued at $337,516,000 after purchasing an additional 140,639 shares during the last quarter. Perceptive Advisors LLC boosted its position in Neurocrine Biosciences by 33.9% during the third quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock valued at $293,629,000 after purchasing an additional 1,214,000 shares during the last quarter. State Street Corp boosted its position in Neurocrine Biosciences by 5.1% during the second quarter. State Street Corp now owns 2,710,196 shares of the company’s stock valued at $124,666,000 after purchasing an additional 131,141 shares during the last quarter. TimesSquare Capital Management LLC boosted its position in Neurocrine Biosciences by 1.4% during the third quarter. TimesSquare Capital Management LLC now owns 2,348,100 shares of the company’s stock valued at $143,892,000 after purchasing an additional 32,727 shares during the last quarter. Finally, Pictet Asset Management Ltd. boosted its position in Neurocrine Biosciences by 18.0% during the third quarter. Pictet Asset Management Ltd. now owns 1,345,855 shares of the company’s stock valued at $82,474,000 after purchasing an additional 204,996 shares during the last quarter.

NBIX has been the subject of several recent research reports. Jefferies Group increased their price target on Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research report on Friday, January 5th. BMO Capital Markets increased their price target on Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Oppenheimer set a $85.00 price target on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Tuesday, December 12th. Needham & Company LLC reissued a “buy” rating and set a $86.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, Leerink Swann reissued an “outperform” rating and set a $83.00 price target (up from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $84.13.

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at $82.17 on Tuesday. Neurocrine Biosciences, Inc. has a 52-week low of $39.21 and a 52-week high of $91.82. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05.

In related news, CEO Kevin Charles Gorman sold 105,983 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $80.25, for a total transaction of $8,505,135.75. Following the completion of the sale, the chief executive officer now directly owns 339,482 shares of the company’s stock, valued at approximately $27,243,430.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director William H. Rastetter sold 9,500 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $90.00, for a total value of $855,000.00. Following the sale, the director now directly owns 34,250 shares of the company’s stock, valued at $3,082,500. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 189,707 shares of company stock valued at $14,975,715. Insiders own 4.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/13/mckinley-capital-management-llc-delaware-invests-10-77-million-in-neurocrine-biosciences-inc-nbix.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply